The estimated Net Worth of Stephen K. Brannan is at least $16.3 Millón dollars as of 8 March 2024. Dr Brannan owns over 7,500 units of Karuna Therapeutics Inc stock worth over $15,701,227 and over the last 5 years he sold KRTX stock worth over $0. In addition, he makes $624,550 as Chief Medical Officer at Karuna Therapeutics Inc.
Dr has made over 32 trades of the Karuna Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of KRTX stock worth $636,600 on 8 March 2024.
The largest trade he's ever made was exercising 25,000 units of Karuna Therapeutics Inc stock on 9 August 2022 worth over $205,500. On average, Dr trades about 7,777 units every 40 days since 2020. As of 8 March 2024 he still owns at least 47,604 units of Karuna Therapeutics Inc stock.
You can see the complete history of Dr Brannan stock trades at the bottom of the page.
Dr. Stephen K. Brannan is the Chief Medical Officer at Karuna Therapeutics Inc.
As the Chief Medical Officer of Karuna Therapeutics Inc, the total compensation of Dr Brannan at Karuna Therapeutics Inc is $624,550. There are 6 executives at Karuna Therapeutics Inc getting paid more, with Steven Paul having the highest compensation of $10,050,700.
Dr Brannan is 65, he's been the Chief Medical Officer of Karuna Therapeutics Inc since . There are 4 older and 10 younger executives at Karuna Therapeutics Inc. The oldest executive at Karuna Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the CEO, Pres & Chairman.
Stephen's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON, MA, 02110.
Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over $496,938,545 worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth $53,814,390 . The most active insiders traders include Health Llc Pure Tech, James Healy y Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of $18,341,187. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth $636,600.
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
Karuna Therapeutics Inc executives and other stock owners filed with the SEC include: